High-density lipoprotein function: Recent advances

Journal of the American College of Cardiology

Volumn 46, Issue 10, 2005, Pages 1792-1798

  Ansell, Benjamin J ^a   Watson, Karol E ^a   Fogelman, Alan M ^a   Navab, Mohamad ^a   Fonarow, Gregg C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 47 123 CHS ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; ATORVASTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN; OXIDIZING AGENT; TORCETRAPIB;

ACUTE PHASE RESPONSE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CELL ASSAY; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; ENZYME SPECIFICITY; HEART PROTECTION; HUMAN; LIPID OXIDATION; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; RISK ASSESSMENT; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS, HDL; OXIDATION-REDUCTION;

EID: 27644587961     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.080     Document Type: Review

References (54)

1. J.R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, A. von Eckardstein HDL and arteriosclerosis beyond reverse cholesterol transport Atherosclerosis 161 2002 1 16
2. A.M. Fogelman When good cholesterol goes bad Nat Med 10 2004 902 903
3. N. Ferre, J. Camps, J. Fernandez-Ballart Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population Clin Chem 49 2003 1491 1497
4. M. Navab, G.M. Anantharamaiah, S.T. Reddy The oxidation hypothesis of atherogenesis the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007
5. M. Syvanne, M. Ahola, S. Lahdenpera High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease J Lipid Res 36 1995 573 582
6. H.B. Brewer Jr High-density lipoproteins a new potential therapeutic target for the prevention of cardiovascular disease Arterioscler Thromb Vasc Biol 24 2004 387 391
7. P.X. Shaw Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the immune responses associated with it Arch Immunol Ther Exp (Warsz) 52 2004 225 239
8. A. Huang, C. Li, R.L. Kao, W.L. Stone Lipid hydroperoxides inhibit nitric oxide production in RAW264.7 macrophages Free Radic Biol Med 26 1999 526 537
9. I. Maor, T. Hayek, R. Coleman, M. Aviram Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 17 1997 2995 3005
10. W. Jessup Oxidized lipoproteins and nitric oxide Curr Opin Lipidol 7 1996 274 280
11. P. Suryaprabha, U.N. Das, G. Ramesh, K.V. Kumar, G.S. Kumar Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus Prostaglandins Leukot Essent Fatty Acids 43 1991 251 255
12. S. Colli, D. Caruso, E. Stragliotto Proinflammatory lipoxygenase products from peripheral mononuclear cells in patients with rheumatoid arthritis J Lab Clin Med 112 1988 357 362
13. J. Frostegard, E. Svenungsson, R. Wu Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations Arthritis Rheum 52 2005 192 200
14. R.A. Memon, I. Staprans, M. Noor Infection and inflammation induce LDL oxidation in vivo Arterioscler Thromb Vasc Biol 20 2000 1536 1542
15. K.E. Watson, S. Hama, G.C. Fonarow, B.J. Ansell, M. Navab, A.M. Fogelman Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, hs-CRP and paraoxonase activity Circulation 110 2004 III52
16. A. Watson, J. Berliner, S. Hama Protective effect of high density lipoprotein associated paraoxonase inhibition of the biological activity of minimally oxidized low density lipoprotein J Clin Invest 96 1995 2882 2891
17. M. Navab, J.A. Berliner, G. Subbanagounder HDL and the inflammatory response induced by LDL-derived oxidized phospholipids Arterioscler Thromb Vasc Biol 21 2001 481 488
18. B. Garner, A.R. Waldeck, P.K. Witting, K.A. Rye, R. Stocker Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII J Biol Chem 273 1998 6088 6095
19. A. Graham, D.G. Hassall, S. Rafique, J.S. Owen Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein Atherosclerosis 135 1997 193 204
20. B.J. Ansell, M. Navab, S. Hama Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
21. D.L. Macdonald, T.L. Terry, L.B. Agellon, P.N. Nation, G.A. Francis Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 23 2003 1583 1588
22. L. Zheng, B. Nukuna, M.L. Brennan Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease J Clin Invest 114 2004 529 541
23. S.J. Nicholls, S.L. Hazen Myeloperoxidase and cardiovascular disease Arterioscler Thromb Vasc Biol 25 2005 1102 1111
24. C. Bergt, S. Pennathur, X. Fu The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport Proc Natl Acad Sci U S A 101 2004 13032 13037
25. J.A. Vita, M.L. Brennan, N. Gokce Serum myeloperoxidase levels independently predict endothelial dysfunction in humans Circulation 110 2004 1134 1139
26. P.T. Kovanen, M.O. Pentikainen Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis Curr Opin Lipidol 14 2003 411 419
27. G.W. Cockerill, K.-A. Rye, J.R. Gamble, M.A. Vadas, P.J. Barter High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler Thromb Vasc Biol 15 1995 1987 1994
28. M. Navab, G.M. Anantharamaiah, S.T. Reddy The double jeopardy of HDL Ann Med 37 2005 1 6
29. P. Barter The inflammation lipoprotein cycle Atheroscler Suppl 6 2005 15 20
30. S. Marchesi, G. Lupattelli, R. Lombardini Acute inflammatory state during influenza infection and endothelial function Atherosclerosis 178 2005 345 350
31. L. Rohrer, M. Hersberger, A. von Eckardstein High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease Curr Opin Lipidol 15 2004 269 278
32. H.J. van Leeuwen, E.C. Heezius, G.M. Dallinga, J.A. van Strijp, J. Verhoef, K.P. van Kessel Lipoprotein metabolism in patients with severe sepsis Crit Care Med 31 2003 1359 1366
33. B.J. Van Lenten, A.C. Wagner, D.P. Nayak, S. Hama, M. Navab, A.M. Fogelman High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection Circulation 103 2001 2283 2288
34. Y. Kumon, Y. Nakauchi, K. Kidawara A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response Scand J Immunol 48 1998 419 424
35. B.G. Brown, X.Q. Zhao, A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
36. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
37. C.D. Furberg The usefulness of information on HDL-cholesterol potential pitfalls of conventional assumptions Curr Control Trials Cardiovasc Med 2 2001 107 108
38. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
39. H.B. Brewer Jr Increasing HDL cholesterol levels N Engl J Med 350 2004 1491 1494
40. B. Angelin, P. Parini, M. Eriksson Reverse cholesterol transport in man promotion of fecal steroid excretion by infusion of reconstituted HDL Atheroscler Suppl 3 2002 23 30
41. M.N. Nanjee, C.J. Cooke, R. Garvin Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans J Lipid Res 42 2001 1586 1593
42. M. Navab, S.Y. Hama, C.J. Cooke Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein step 1 J Lipid Res 41 2000 1481 1494
43. J.J. Badimon, L. Badimon, V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234
44. C.R. Sirtori, L. Calabresi, G. Franceschini Cardiovascular status of carriers of the apolipoprotein A-I Milano mutant the Limone sul Garda study Circulation 103 2001 1949 1954
45. S.E. Nissen, T. Tsunoda, E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial JAMA 290 2003 2292 2300
46. M. Navab, G.M. Anantharamaiah, S.T. Reddy Apolipoprotein A-I mimetic peptides Arterioscler Thromb Vasc Biol 25 2005 1325 1331
47. M. Navab, G.M. Anantharamaiah, S. Hama Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol Circulation 105 2002 290 292
48. M. Navab, G.M. Anantharamaiah, S.T. Reddy Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 2004 3215 3220
49. B.J. Van Lenten, A.C. Wagner, M. Navab D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes Circulation 110 2004 3252 3258
50. M. Navab, S.Y. Hama, S.T. Reddy Oxidized lipids as mediators of coronary heart disease Curr Opin Lipidol 13 2002 363 372
51. S. Cuzzocrea, L. Dugo, N.S. Patel High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis Shock 21 2004 342 351
52. M.C. McDonald, P. Dhadly, G.W. Cockerill Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock Shock 20 2003 551 557
53. S. Zhong, D.S. Sharp, J.S. Grove Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917 2923
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497